Pirtobrutinib clinical trials

Explore recruiting pirtobrutinib clinical trials.

Recruiting pirtobrutinib studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Pirtobrutinib trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 3, Open-Label, Randomized Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Sweden, Belgium, Spain, Germany, Austria, Netherlands +4 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

PirtobrUtinib as frontline Therapy for elderly unfit/frail patient with MAntle cell lymphoma: a phase II study of the Fondazione Italiana Linfomi (FIL)

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

HOVON 180 CLL: Prospective phase II trial of pirtobrutinib treatment (24 cycles) with 12 cycles of epcoritamab in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma. ODYSSEUS study (Outcome-Driven trial for relapsed CLL/SLL combining BTK and bispecific antibodY to improve outcome)

Netherlands

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 1/2, Dose-finding Study Investigating the Safety and Efficacy of Pirtobrutinib in Adults with Immune Thrombocytopenia

France, Italy, Denmark, Spain, Poland, Norway

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Study PACIFIC: Fixed duration treatment with combined pirtobrutinib and short course immuno-chemotherapy in fit patients with previously untreated symptomatic chronic lymphocytic leukemia (CLL). A phase II FILO trial

France

Therapeutic exploratory (Phase II) EU CTIS Study details

A prospective, open-label, randomized, multicenter phase-III trial to evaluate the efficacy of pirtobrutinib and epcoritamab compared with R-(mini)-CHOP for treatment of patients with Richter Transformation - CLLRT2

Austria, Germany, Denmark, Ireland

Therapeutic confirmatory (Phase III) EU CTIS Study details

Pirtobrutinib trials by city

Pirtobrutinib in Toronto Pirtobrutinib in Vancouver Pirtobrutinib in Montreal Pirtobrutinib in Calgary Pirtobrutinib in Edmonton Pirtobrutinib in Ottawa Pirtobrutinib in Winnipeg Pirtobrutinib in Quebec City Pirtobrutinib in Hamilton Pirtobrutinib in Kitchener Pirtobrutinib in London Pirtobrutinib in Halifax Pirtobrutinib in New York Pirtobrutinib in Los Angeles Pirtobrutinib in Chicago Pirtobrutinib in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease